Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 12:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 125 matching trials from the live ClinicalTrials.gov search.
Conditions
Hematopoietic Stem Cell Transplant
Interventions
PATH
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Durham, North Carolina
Conditions
Gastrointestinal Stromal Tumor
Interventions
regorafenib
Drug
Lead sponsor
Suzanne George, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Bortezomib Plus Rituximab for EBV+ PTLD

NCT01058239
Conditions
Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant), Epstein Barr Virus Infections
Interventions
bortezomib, rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Desmoid, Desmoid; Abdominal, Pregnancy Loss, Pregnancy Complications
Interventions
Pregnancy
Other
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myelodysplastic Syndrome
Interventions
bortezomib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Dose-Intense Temozolomide in Recurrent Glioblastoma

NCT00657267
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide
Drug
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Boston, Massachusetts • Lebanon, New Hampshire • Winston-Salem, North Carolina + 1 more
Conditions
Hematologic Malignancy
Interventions
Infusion of donor dendritic cells, Infusion of donor lymphocytes
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Minneapolis, Minnesota • Salt Lake City, Utah
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
CT-2103 (Xyotax)
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of 500mg of Fulvestrant

NCT00585507
Conditions
Breast Cancer
Interventions
Fulvestrant
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Lowell, Massachusetts • South Weymouth, Massachusetts
Conditions
Hepatocellular Cancer
Interventions
Sorafenib, radiofrequency ablation
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Liver Cancer
Interventions
Proton Beam Irradiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Conditions
Neuroendocrine Tumors
Interventions
Bevacizumab, Temozolomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituxan, 1018 ISS
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Small Cell Lung Cancer, Lung Cancer, SCLC
Interventions
Pazopanib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Multiple Myeloma
Interventions
Dendritic Cell Tumor Fusion Vaccine
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Immune Checkpoint Inhibitor-Related Colitis
Interventions
Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsules, Placebo Vedolizumab, Sulfamethoxazole-Trimethoprim, Placebo for Sulfamethoxazole-Trimethoprim
Drug · Other
Lead sponsor
Shilpa Grover, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Multiple Myeloma
Interventions
bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Buffalo, New York + 1 more
Conditions
Adenocarcinoma, Non-small Cell Lung Cancer
Interventions
Erlotinib
Drug
Lead sponsor
Pasi A. Janne, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Lymphoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Amifostine, Radiation Therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
35 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Prostate Cancer
Interventions
Questionnaire
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
9
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 5 more